missilealphabet.mystrikingly.com Open in urlscan Pro
52.84.150.45  Public Scan

Form analysis
0 forms found in the DOM

Text Content

EDUCATION.COM


 * Big Media
 * Recent
 * Posts
 * “The more that you read,
 * Subscribe
 * …  
   * Big Media
   * Recent
   * Posts
   * “The more that you read,
   * Subscribe




EDUCATION.COM


 * Big Media
 * Recent
 * Posts
 * “The more that you read,
 * Subscribe
 * …  
   * Big Media
   * Recent
   * Posts
   * “The more that you read,
   * Subscribe





IASO BIO ESTABLISHES INTERNATIONAL CAR-T DIAGNOSTIC AND TREATMENT CENTER IN
CHINA TO SERVE MM PATIENTS WORLDWIDE

November 21, 2023

NANJING, China, Nov 21 (Bernama-BUSINESS WIRE) -- Nanjing IASO Biotechnology
Co., Ltd. (IASO Bio) made its debut at the 6th China International Import Expo
(CIIE) with FUCASO, the world's first fully-human CAR-T, and entered into a
strategic partnership with several international medical institutions, bringing
hope for cure to multiple myeloma (MM) patients worldwide.

On June 30, 2023, the China National Medical Products Administration (NMPA)
approved the marketing of Equecabtagene Autoleucel Injection (brand name:
FUCASO) for the treatment of adult patients with relapsed or refractory multiple
myeloma (r/rMM). Meanwhile, the Equecabtagene Autoleucel Injection has received
the Orphan Drug Designation, as well as the Regenerative Medicine Advanced
Therapy and Fast Track Designations from the U.S. Food and Drug Administration,
and has been approved for clinical trials in the U.S.

A single infusion of FUCASO can lead to lasting and deep remission with a
favorable safety profile in patients with r/rMM who have failed multiple lines
of therapy. Due to its unique design, FUCASO, as a fully-human CAR-T therapy, is
able to persist in patients for a longer period of time, offering hope for
overcoming the challenging problem of relapsed MM.

FUCASO has attracted patients from numerous countries around the world to seek
treatment in Chinese hospitals in just 4 months since its approval for marketing
in China. These hospitals have a world-leading level of full-process management
in CAR-T therapy. In addition, the cost of treatment with FUCASO in China is
significantly lower than that of similar products in Europe and America, which
has benefited more patients worldwide.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20231115683764/en/

Contact

Company: Nanjing IASO Biotechnology Co., Ltd
Contact Person: Zhang Yuanyuan
Email: Med-service@iasobio.com
Website: https://i-connection.iasobio.com/en
Telephone: 400 966 5315

Source : Nanjing IASO Biotechnology Co., Ltd

Previous
UNLOCKING THE FUTURE: UNIVERSITI TUN ABDUL RAZAK ...
Next

 Return to site
 *  * 
    * 
    * 
    * 

Powered by Strikingly